(Bloomberg) -- Sanofi’s top medical and digital officer, Ameet Nathwani, is among four senior executives leaving the pharmaceutical giant as Chief Executive Officer Paul Hudson reshapes the company’s strategy.

Also on their way out are Dieter Weinand, head of primary care; Dominique Carouge, who leads business transformation; and Kathleen Tregoning, head of external affairs, Sanofi said in response to questions from Bloomberg News Tuesday.

The executive moves follow Hudson’s plan unveiled in December to rejuvenate the French drugmaker and fire up a drug pipeline that’s been slow to deliver. Sanofi is ending its hunt for new diabetes and heart disease drugs, helping save more than $2 billion as the CEO bets on fields like cancer that are ripe for innovation.

Nathwani was named chief medical officer in 2016 and added the chief digital officer role a year ago. Sanofi highlighted the potential of new technologies in naming Hudson -- a former executive at Swiss rival Novartis AG -- as CEO last year and credited his accomplishments in the digital space.

Read this: Sanofi’s CEO Quits Diabetes as Cancer Breakthroughs Beckon

Hudson, who took over in September, told investors last week he’s shrinking the committee of top executives to 10 from 14 as part of the broader effort to shake up Sanofi. The company said the leaner structure would speed up decision making.

The shares traded as much as 0.8% lower early Wednesday in Paris. They’ve risen 24% over the past 12 months.

The company in 2018 brought in research chief John Reed from Roche Holding AG and Jean-Baptiste Chasseloup de Chatillon as chief financial officer.

(Updates with shares, executive appointments in last two paragraphs)

To contact the reporter on this story: James Paton in London at jpaton4@bloomberg.net

To contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, Kenneth Wong

©2020 Bloomberg L.P.